Copy
View this email in your browser
Dear Reader,

Mike's Blog October 2020

As fall begins and with multiple promising treatment approaches to improve outcomes in COVID-19 coming to light, it is of critical need to rapidly implement trials to further study and confirm (or reject) these preliminary findings through well-designed randomized controlled clinical trials. As such, the resources, infrastructure and expertise throughout the CTSA consortium – including our Trial Innovation Network (TIN), our network of sites, partners and collaborators – provide  ideal conditions and the necessary capacity to quickly move from observations in the field and/or in the laboratory to confirmatory testing of hypotheses through the implementation of larger multi-site-controlled trials.  Below are some studies where our CTSA Program is leading the way and playing a critical role. Read More

THE SPOTLIGHT


CTSA Program Feedback Responses and Notice of Change to Key Dates for PAR-18-940

NCATS received input from stakeholder communities on how the CTSA Program might be strengthened to deliver on its promise to develop, demonstrate and disseminate innovative approaches, methodologies and interventions that translate into improved human health. Feedback was received from a diverse audience including: general feedback from CTSA Program review panel, Working Groups and Public & CTSA Program Consortium members via Request for Information (RFI) in October 2019, including feedback from academic centers (individuals and institutions); advocacy groups; medical and scientific societies; not-for-profit, integrated health system; and an NIH institute. Over 100 comments were received.  We have published the responses to the feedback via an Information Session accessible through the following URL:  https://www.youtube.com/watch?v=GgIppY4ba54&feature=youtu.be.  Please provide feedback regarding the session by “liking” (or not) the presentation in YouTube. 

In addition, we recently issued a Notice of Change to Key Dates for PAR-18-940 “Clinical and Translational Science Award (U54 Clinical Trial Optional)” NOT-TR-20-036. The purpose of this notice is to inform interested applicants in a change to the Key Dates for PAR-18-940 “Clinical and Translational Science Award (U54 Clinical Trial Optional)”. The August 15, 2021 receipt date has been moved to July 15, 2021.


WHAT'S NEW


Secure Your Hub’s Spot at the Virtual CTSA Program Meeting Poster Session this Fall!

This year’s Fall CTSA Program Meeting will host a virtual Networking & Poster Session on Friday, November 20th.  The timing is not confirmed yet. 

Details:

  • Poster Session Theme: Innovative Approaches and Solutions to Common Translational Science Problems, in particular, consideration of COVID accommodations.
  • One poster per CTSA Program hub or coordinating center is permitted
  • Be sure to highlight your organization’s vision / successes
  • Electronic versions of the abstract and poster will be available for viewing on the CLIC website

If you are planning to submit a poster, please complete this brief form (CLIC log-in required) now to confirm your spot! Only preliminary details are required upon submission.

Deadline for Initial Poster Submission: Thursday, October 22, 2020

Final poster details including abstract & PNG or JPG of poster must be uploaded to the CLIC website by Thursday, October 29, 2020.

Login & Register Now!

Meeting Highlights:Twitter handle #2020CTSAProgramMtg
Have any questions? Click here to access CTSA Program Virtual Meeting FAQs
For additional assistance, contact us at program_meetings@clic-ctsa.org.

 

Pregnancy & Social Determinants of Health Domain Teams Address Conditions Affected by COVID-19 with N3C Data

N3C Domain Teams enable researchers with shared interests analyze data within the N3C Data Enclave and collaborate more efficiently in a team science environment. Multi-discipline Clinical Domain Teams comprised of clinical and subject matter experts, statisticians, informaticists, and machine learning specialists focus on clinical questions surrounding COVID-19's impact on health, whereas the Cross-Cutting Domain Teams have a varied focus that apply to multiple domains. These teams provide an opportunity to collect pilot data for grant submissions, train algorithms on larger datasets, and learn how to use tools for large-scale COVID-19 data. 

2021 Supporting Instructions for Research Performance Progress Reports (RPPRs) for CTSAs

We have released the supporting instructions for RPPRs for the CTSA program hubs. These instructions are not in replacement of the NIH RPPR instruction guide but are an aid to CTSA Program awardees in the submission of CTSA specific information in their annual RPPR. For questions/comments related to the supporting instructions please email us at: CTSARPPRQuestions@mail.nih.gov

CTSA Program Diversity and Re-Entry Supplements

The CTSA Program supports Diversity and Re-Entry Research Supplements to active and eligible UL1 grants through the following funding opportunity announcements (FOAs): For Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed) follow: PA-20-022. For Research Supplements to Promote Re-Entry into Biomedical and Behavioral Research Careers (Admin Supp - Clinical Trial Not Allowed) follow: PA-18-592 (may be updated soon). Next due date is November 1, 2020. All administrative supplements are required to be submitted electronically NOT-OD-20-128. Note: the diversity supplement FOA will be re-issued in October: NOT-OD-20-170  “to include new instructions and reflect changes in NIH submission processes announced earlier this year.”

NCATS POC: Xinzhi Zhang, MD, PhD (or your Program Officer).

Administrative Supplements to NCATS CTSA Program KL2 Institutional Career Development Awards as part of the INCLUDE (NOT-OD-21-001)

This Notice of Special Interest (NOSI) announces NIH support for the professional development of early career scientists aiming to establish a career in DS-related research. By providing these scientists with career development research experiences , resources, and mentorship, the NIH intends to foster a pipeline of investigators in DS and other intellectual disabilities who will lead future research to improve the understanding of the biology of DS and support development of new treatments for health conditions experienced by those with DS. Next due date is November 2, 2020. NCATS POC: Erica.Rosemond

NIH Loan Repayment Programs (LRPs)

NCATS participates in the Clinical Research, Pediatric Research and Health Disparity Research LRPs. Educational loan repayment maximum up to $100K over 2 years (Depending on debt level). Two-year initial contracts with 1 or 2 year competitive renewals. Online Application Period is from Sept 1, 2020 to Nov 20, 2020. NCATS POC: David Wilde, MD, PhD

GET INVOLVED


View News Button
View Funding Opportunities button
View Meetings & Events Button
View Education Button
CONNECT WITH NCATS
ncats.nih.gov
NCATS Facebook NCATS Twitter NCATS Linkedin
CONNECT WITH CLIC
clic-ctsa.org
CLIC Twitter
Copyright © 2020 CLIC, All rights reserved.


Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.